PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
We focus on discovering and developing innovative gene-based immuno-oncology treatments for solid tumors using our proprietary intravenously administered T-SIGn virus platform. Our portfolio of differentiated gene therapy products are all delivered systemically but act locally within the tumor.
At PsiOxus we are advancing our internal early and clinical stage candidates and establishing strategic partnerships with immuno-oncology leaders to bring our cancer gene therapy products to patients.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature